JRCT ID: jRCT2041210129
Registered date:19/01/2022
Phase Ib/II Study of the Combination of Tucidinostat and Rituximab in Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | B-cell Non-Hodgkin's Lymphoma |
Date of first enrollment | 23/05/2022 |
Target sample size | 71 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | Patients will receive tucidinostat at 40 mg QD twice weekly with a 3 to 4 day interval between doses and rituximab at 375 mg/m^2 on Day 1 of each Cycle in 21 day treatment cycles |
Outcome(s)
Primary Outcome | ORR at 6 to 8 weeks after the last dose of rituximab |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | 1) Part A: Patients with diagnosed B-NHL, Part B: Patients with diagnosed DLBCL 2) Patients who have relapsed or refractory following at least one systemic therapy 3) Patients who have had response to a previous treatment regimen that included anti CD20 therapy at least once 4) Patients who have normal systemic organ function |
Exclude criteria | 1) Patients with known double hit/triple hit lymphoma 2) Patients with bulky disease 3) Patients with a history or findings of cardiac disorders 4) Patients with gastrointestinal disorders or dysphagia which could affect oral medicine administration and absorption 5) Patients with a history of clinically significant pulmonary disorders (including interstitial lung disease, pneumonitis, obstructive pulmonary disease, and bronchospasm) 6) Patients with a history of or complications of other malignancies that have not been in remission for at least the last 5 years (except some cases) 7) Patients who are deemed by the principal investigator or sub-investigator to be unsuitable for participation in the study due to significant clinical findings, abnormal laboratory results, psychiatric disorders, or other conditions that could affect the results of the study |
Related Information
Primary Sponsor | Hatake Kiyohiko |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Clinical Development Dept. |
Address | 2-4-16, Kyobashi, Chuo-ku, Tokyo Tokyo Japan 104-8002 |
Telephone | +81-3-3273-3746 |
clinical-trials@meiji.com | |
Affiliation | Meiji Seika Pharma Co., Ltd. |
Scientific contact | |
Name | Kiyohiko Hatake |
Address | 8-5-35, Akasaka, Minato-Ku, Tokyo Tokyo Japan 107-0052 |
Telephone | +81-3-3273-7346 |
clinical-trials@meiji.com | |
Affiliation | Junwakai Medical Foundation Incorporated Sanno Medical Center |